Instem plc Customer Wins for New Provantis Release
April 18 2013 - 2:00AM
RNS Non-Regulatory
TIDMINS
Instem plc
18 April 2013
18 April 2013
RNS Reach
Instem plc
("Instem", or, the "Company")
Additional Customer Wins for New Provantis Release
Strong customer uptake of major new upgrade of Provantis
Instem (AIM:INS), a leading provider of IT solutions to the
global early development healthcare market, is pleased to announce
its latest new customer signing and additional client upgrades for
Provantis 9, the next generation of Provantis, Instem's study
management software suite.
The latest new customer signing is a leading Chinese government
research laboratory, while existing clients upgrading to the new
release in recent months include the M.D. Anderson Cancer Center,
Roche, the NIEHS, a global top 10 pharma company, a mid-tier French
pharma company and a leading American multi-national chemical
corporation. These sign-ups and upgrades bring to 17 the total
number of sites implementing Provantis 9, building on a good level
of signings in 2012, which included the US National Institute of
Allergy and Infectious Diseases, the Beijing National Centre for
the Safety Evaluation of Drugs, Lovelace Respiratory Research,
Seventh Wave and JOINN Laboratories. Three quarters of these
Provantis 9 sites are in the US and China with the balance in
Europe.
Provantis 9 represents a major new release of Instem's core
product suite. It was delivered in July 2012 after Instem completed
a significant, phased multi-year product redevelopment, designed to
further enhance efficiencies and reduce study timelines while
supporting the changes in laboratory working practices brought
about by the structural changes in the pharma market. It takes
advantage of the latest capabilities of the underlying Microsoft(R)
and Oracle(R) platform technologies. Customer feedback indicates
that unique Provantis capabilities that improve operational
efficiency and reduce study timelines are proving to be compelling
differentiators in their selection of study management
software.
Phil Reason, CEO of Instem plc, commented, "Instem is delighted
with the very positive response so far to Provantis 9 from both
existing and new customers, particularly those in Europe where the
pharma market is recovering more slowly. We are committed to
remaining at the forefront of the early development study
management industry, providing our clients with the tools to bring
new products safely and efficiently to market. We are seeing strong
uptake not only from current customers looking to achieve
additional levels of automation and efficiency, but also from new
customers in key emerging markets such as China. Instem is now
firmly established as the leading provider in China, which is on
track to become the second largest pharmaceutical market in the
world after the US."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser &
Broker) +44 (0) 20 7496 3000
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Caroline Evans-Jones
Fiona Conroy
About Instem plc
Instem is a leading supplier of IT applications to the early
development healthcare market delivering compelling solutions for
data collection, management and analysis across the R&D
continuum. Instem applications are used by customers worldwide,
meeting the rapidly expanding needs of life science and healthcare
organisations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem supports its clients through full service offices in the
United States, United Kingdom and China with additional locations
in India and a full service distributor based in Japan.
To learn more about Instem solutions and its mission, please
visit www.instem.com or its investor centre
http://investors.instem.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKLXFDDDEFF
Instem (LSE:INS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Instem (LSE:INS)
Historical Stock Chart
From Aug 2023 to Aug 2024